Skip to main content
L

Lunaphore

Lunaphore is a Swiss life sciences firm developing microfluidic chip technology and the COMET™ platform for multiplex spatial proteomic and transcriptomic analysis of tumours and tissues.

Lunaphore is a Swiss life sciences company founded in 2014 that develops microfluidic chip technology for extracting spatial proteomic and transcriptomic data from tumours and other tissues. Its approach converts simple assays into multiplex spatial biology without added complexity, a capability intended to bring spatial analysis within reach of ordinary laboratories rather than specialised facilities alone.

The company's flagship product, the COMET™ platform, is a fully automated, high-throughput spatial biology system spanning the workflow from assay development to cohort analysis. The stated turnaround time from assay development to cohort analysis is a matter of weeks. Notably, the platform works with off-the-shelf, label-free primary antibodies rather than proprietary formulations, avoiding the reagent lock-in common to competing approaches. Technical domains covered include spatial proteomics, spatial transcriptomics, multiplexed tissue analysis, multiomics, immunohistochemistry and integration of RNAscope™ technology.

Applications of the technology span immuno-oncology, neuroscience, immunology and broader oncology research, as well as pharmaceutical R&D and the development of personalised medicines and next-generation therapies. The company forms part of Bio-Techne's Spatial Biology Division alongside ACD's RNAscope™ technology, and is headquartered in Switzerland.

Many members of the team are former researchers, and the company's stated aim is to make spatial biology accessible to every laboratory. Researcher flexibility is a recurring theme: an open antibody ecosystem, ease of use and reduced complexity are positioned as ways to accelerate scientific discovery.

Open jobs